See more : Union Quality Plastics Limited (UNQTYMI.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Calliditas Therapeutics AB (publ) (CALT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Calliditas Therapeutics AB (publ), a leading company in the Biotechnology industry within the Healthcare sector.
- Eevia Health Plc (EEVIA.ST) Income Statement Analysis – Financial Results
- Avantium N.V. (AVTXF) Income Statement Analysis – Financial Results
- Diadrom Holding AB (publ) (DIAH.ST) Income Statement Analysis – Financial Results
- Prosperity Bancshares, Inc. (PB) Income Statement Analysis – Financial Results
- Puravankara Limited (PURVA.NS) Income Statement Analysis – Financial Results
Calliditas Therapeutics AB (publ) (CALT)
About Calliditas Therapeutics AB (publ)
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.21B | 802.88M | 229.35M | 874.00K | 184.83M | 0.00 | 0.00 | 497.00K | 478.00K |
| Cost of Revenue | 77.06M | 15.20M | 0.00 | 0.00 | 0.00 | 51.00K | 51.00K | 56.52M | 51.39M |
| Gross Profit | 1.13B | 787.68M | 229.35M | 874.00K | 184.83M | -51.00K | -51.00K | -56.02M | -50.91M |
| Gross Profit Ratio | 93.62% | 98.11% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | -11,271.63% | -10,650.84% |
| Research & Development | 499.54M | 414.75M | 357.49M | 241.37M | 149.83M | 99.26M | 384.00K | 40.28M | 36.89M |
| General & Administrative | 332.99M | 259.47M | 210.63M | 102.76M | 62.88M | 133.15M | 84.60M | 56.41M | 51.28M |
| Selling & Marketing | 727.74M | 515.19M | 179.60M | 38.96M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.01B | 774.66M | 390.23M | 141.72M | 62.88M | 133.15M | 84.60M | 56.41M | 51.28M |
| Other Expenses | 0.00 | 20.21M | 6.09M | 0.00 | 0.00 | 51.00K | 51.00K | 112.00K | 111.00K |
| Operating Expenses | 1.51B | 1.21B | 753.80M | 383.10M | 212.71M | 133.20M | 84.65M | 56.52M | 51.39M |
| Cost & Expenses | 1.59B | 1.22B | 753.80M | 383.10M | 212.71M | 133.20M | 84.65M | 56.52M | 51.39M |
| Interest Income | 29.10M | 50.20M | 102.00K | 547.00K | 926.00K | 6.00K | 0.00 | 2.00K | 0.00 |
| Interest Expense | 73.20M | 12.53M | 7.11M | 393.00K | 325.00K | 8.00K | 2.24M | 1.01M | 9.00K |
| Depreciation & Amortization | 16.59M | 12.91M | 34.43M | 2.82M | 1.82M | 51.00K | 51.00K | 112.00K | 111.00K |
| EBITDA | -367.80M | -388.82M | -483.94M | -379.40M | -25.13M | -133.14M | -84.60M | -56.40M | -51.28M |
| EBITDA Ratio | -30.48% | -52.55% | -228.67% | -43,346.80% | -13.60% | 0.00% | 0.00% | -11,348.69% | -10,727.62% |
| Operating Income | -384.40M | -421.94M | -524.46M | -379.72M | -28.02M | -132.48M | -84.51M | -56.02M | -50.91M |
| Operating Income Ratio | -31.85% | -52.55% | -228.67% | -43,446.22% | -15.16% | 0.00% | 0.00% | -11,271.63% | -10,650.84% |
| Total Other Income/Expenses | -72.62M | 5.39M | 9.47M | -53.93M | -4.48M | 1.15M | -2.29M | -395.00K | 375.00K |
| Income Before Tax | -457.02M | -409.42M | -513.37M | -436.15M | -32.50M | -132.05M | -86.79M | -56.91M | -51.01M |
| Income Before Tax Ratio | -37.87% | -50.99% | -223.84% | -49,902.86% | -17.58% | 0.00% | 0.00% | -11,451.11% | -10,672.38% |
| Income Tax Expense | 9.17M | 2.85M | -3.84M | 360.00K | 77.00K | 441.00K | 2.24M | 1.01M | 9.00K |
| Net Income | -466.19M | -412.27M | -509.54M | -436.51M | -32.58M | -132.05M | -86.79M | -56.91M | -51.01M |
| Net Income Ratio | -38.63% | -51.35% | -222.17% | -49,944.05% | -17.63% | 0.00% | 0.00% | -11,451.11% | -10,672.38% |
| EPS | -8.69 | -7.78 | -10.02 | -9.73 | -0.88 | -5.09 | -5.81 | -1.71 | -1.54 |
| EPS Diluted | -8.69 | -7.78 | -10.02 | -9.73 | -0.88 | -5.09 | -5.81 | -1.71 | -1.54 |
| Weighted Avg Shares Out | 53.67M | 53.02M | 50.83M | 44.87M | 36.94M | 25.95M | 14.93M | 33.23M | 33.23M |
| Weighted Avg Shares Out (Dil) | 53.67M | 53.02M | 50.83M | 44.87M | 36.94M | 25.95M | 14.93M | 33.23M | 33.23M |
Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib
Calliditas Therapeutics AB Sponsored ADR (CALT) Moves 12.8% Higher: Will This Strength Last?
Calliditas Therapeutics: Good Long-Term Data Could Boost Tarpeyo Sales
Calliditas to participate in upcoming investor conferences
3 Supercharged Stocks Near 52-Week Highs That Could Keep Climbing
New Strong Sell Stocks for February 27th
Calliditas: Underfollowed Swedish Biotech Focusing On Rare Kidney Disease
Calliditas: Low Cash And Unconvincing Pipeline
New Strong Sell Stocks for January 6th
Calliditas' Kinpeygo Receives CHMP Backing For Kidney Disease
Source: https://incomestatements.info
Category: Stock Reports